2 weeks Ago By ABMN Staff
Prudential Financial Inc. lifted its position in Mineralys Therapeutics, Inc. ( NASDAQ:MLYS – Free Report ) by 85.
7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 125,650 shares of the company’s stock after purchasing an additional 58,000 shares during the period. Prudential Financial Inc.
’s holdings in Mineralys Therapeutics were worth $1,547,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors also recently bought and sold shares of the company. China Universal Asset Management Co.
Ltd. lifted its holdings in shares of Mineralys Therapeutics by 10.3% in the 4th quarter.
China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company’s stock worth $130,000 after buying an additional 989 shares during the period.
AlphaQuest LLC raised its holdings in shares of Mineralys Therapeutics by 2,637.8% in the fourth quarter. AlphaQuest LLC now owns 15,222 shares of the company’s stock valued at $187,000 after acquiring an additional 14,666 shares in the last quarter.
SG Americas Securities LLC lifted its stake in Mineralys Therapeutics by 119.0% in the fourth quarter. SG Americas Securities LLC now owns 19,961 shares of the company’s stock worth $246,000 after acquiring an additional 10,845 shares during the period.
Proficio Capital Partners LLC bought a new position in Mineralys Therapeutics during the 4th quarter worth about $285,000. Finally, Verition Fund Management LLC increased its position in Mineralys Therapeutics by 30.6% during the 3rd quarter.
Verition Fund Management LLC now owns 27,361 shares of the company’s stock valued at $331,000 after purchasing an additional 6,408 shares during the period. Institutional investors own 84.46% of the company’s stock.
Mineralys Therapeutics Stock Down 8.4 % NASDAQ:MLYS opened at $12.40 on Friday.
The stock has a market capitalization of $778.53 million, a price-to-earnings ratio of -3.41 and a beta of -0.
39. Mineralys Therapeutics, Inc. has a 52 week low of $8.
24 and a 52 week high of $18.38. The firm has a 50 day moving average of $11.
90 and a 200 day moving average of $12.28. Insider Transactions at Mineralys Therapeutics In other news, Director Ra Capital Management, L.
P. bought 1,296,296 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were purchased at an average price of $13.
50 per share, for a total transaction of $17,499,996.00. Following the completion of the transaction, the director now directly owns 4,280,051 shares in the company, valued at approximately $57,780,688.
50. This represents a 43.45 % increase in their ownership of the stock.
The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website . Also, CFO Adam Scott Levy sold 10,757 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $9.
10, for a total transaction of $97,888.70. Following the transaction, the chief financial officer now directly owns 226,097 shares of the company’s stock, valued at $2,057,482.
70. This represents a 4.54 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Over the last 90 days, insiders have sold 84,861 shares of company stock worth $1,142,937. Insiders own 33.
24% of the company’s stock. Analysts Set New Price Targets Several brokerages have recently weighed in on MLYS. HC Wainwright upped their price target on shares of Mineralys Therapeutics from $30.
00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday. The Goldman Sachs Group dropped their target price on Mineralys Therapeutics from $28.
00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, Guggenheim reissued a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, February 24th.
View Our Latest Research Report on Mineralys Therapeutics About Mineralys Therapeutics ( Free Report ) Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. Further Reading Want to see what other hedge funds are holding MLYS? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Mineralys Therapeutics, Inc. ( NASDAQ:MLYS – Free Report ). Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
